Celgene’s Otezla® (apremilast) receives European marketing authorisation

Celgene UK announced that the European Commission has licenced Otezla®, the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: (2)

For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
Alone or in combination with disease-modifying antirheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

Source: Pharmacy Europe - January 16, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Dermatology Rheumatology Patient care chronic plaque psoriasis DMARD Latest News PDE4 inhibitor psoriatic arthritis PUVA Source Type: news